Science

Are antidepressants are a health risk? This study says yes.

Are antidepressants a health risk? Researchers at the University of McMaster in Hamilton have released a study on the health impacts of long-term antidepressant use, arguing that the commonly-prescribed medications raise the risk of death by as much as 33 per cent. The study has already produced a strong reaction from some in the medical community who say that the authors’ interpretation of the results is misleading.

Used by about nine per cent of the Canadian adult population to treat anxiety and depression, antidepressants are now one of the country’s most-prescribed drugs. Statistics show their use in Canada has shot up over the past two decades (but has now apparently levelled off), with Canada now one of the top countries in the world for antidepressant use per capita.

Most-prescribed are the SSRI’s (selective serotonin re-uptake inhibitors) which work by increasing the amount of serotonin, a neurotransmitter known to regulate mood, in the brain. Yet, SSRIs have their effect beyond the brain, argue the new study’s authors, who point out that serotonin is also important for proper functioning of other major organs such as the heart, liver, lungs and kidneys.

To that end, the researchers conducted a review and analysis of past studies involving antidepressant-related mortality, finding 17 studies that met their search criteria. The studies, involving hundreds of thousands of patients, showed that antidepressant use is correlated with a 33 per cent higher risk of death and with a 14 per cent higher risk of cardiovascular events like strokes and heart attacks.

Depression itself comes with negative health correlates, such as increased risk of stroke, heart attack and suicide, which make up part of the reason why physicians prescribe the drugs — the thinking being that, overall, taking them will be more helpful than harmful.

“Our findings are important because they undermine this assumption,” says Mara Maslej of McMaster’s Department of Psychology, Neuroscience and Behaviour and study co-author, in a press release. “I think people would be much less willing to take these drugs if they were aware how little is known about their impact outside of the brain, and that what we do know points to an increased risk of death.”

 

Yet the findings have been met with criticism from health experts who claim that they overstate the case. Speaking to the Daily Mail, professor David Baldwin, chairman of the Royal College of Psychiatrists in the United Kingdom said, “Depressed patients have higher risks of a range of physical health problems, all of which carry a risk of increased mortality, and antidepressants are often prescribed for a range of problems other than depression, including chronic pain and insomnia, which also increase mortality.”

The study’s authors underline that while their results showed only a statistically insignificant increase in the risk of death for the general population of the study, that included patients with cardiovascular issues (and serotonin works as a blood thinner, thereby making SSRIs a protective measure for those patients). Removing that group from the analysis and controlling for depression resulted in the 33 per cent higher risk for the population without cardiovascular issues.

“The results support the hypothesis that antidepressants are harmful in the general population but less harmful in cardiovascular patients,” say the study’s authors. Their results are published in the journal Psychotherapy and Psychosomatics.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

4 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

15 hours ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

17 hours ago

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

1 day ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

2 days ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

2 days ago